Dimiracetam - Neurotune

Drug Profile

Dimiracetam - Neurotune

Alternative Names: BND-11624; NT-11624

Latest Information Update: 02 Oct 2015

Price : $50

At a glance

  • Originator Brane Discovery
  • Developer Brane Discovery; Neurotune
  • Class Non-opioid analgesics; Nootropics; Pyrrolidinones; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuropathic pain
  • No development reported Musculoskeletal pain

Most Recent Events

  • 02 Oct 2015 No recent reports of development identified - Phase-I for Musculoskeletal pain (In volunteers) in Switzerland (PO)
  • 02 Oct 2015 No recent reports of development identified - Phase-II for Neuropathic pain in South Africa (PO)
  • 14 Dec 2011 US FDA approves IND application for dimiracetam in Neuropathic pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top